Drug Enforcement Agency: COVID-19 FAQs
STATUS: Active, see temporary extension until Nov. 11, 2024.
Drug Enforcement Agency: Buprenorphine and Telephone
STATUS: Active, see temporary extension until Nov. 11, 2024.
Drug Enforcement Agency: Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medication
STATUS: The full set of telemedicine flexibilities regarding prescription of controlled medications as were in place during the COVID-19 PHE will remain in place through November 11, 2023. Additionally, for any practitioner-patient telemedicine relationships that have been or will be established on or before November 11, 2023, the full set of telemedicine flexibilities regarding prescription of controlled medications as were in place during the COVID-19 PHE will continue to be permitted via a one-year grace period through November 11, 2024. In other words, if a patient and a practitioner have established a telemedicine relationship on or before November 11, 2023, the same telemedicine flexibilities that have governed the relationship to that point are permitted until November 11, 2024.
Drug Enforcement Agency: Announcement on COVID Prescribing Flexibilities
STATUS: Proposes permanent changes.
Drug Enforcement Agency: Proposed Rule on Prescribing Controlled Substances.
STATUS: Proposes permanent changes.
Drug Enforcement Agency: Proposed rule on Expansion of Induction of Buprenorphine via Telemedicine
STATUS: Proposes permanent changes.
READ LESS